FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...